MLN 3701

Drug Profile

MLN 3701

Alternative Names: AVE 1701; Inflammation therapy - sanofi-aventis/Millennium; MLN3701

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals; sanofi-aventis
  • Developer Millennium
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

  • 17 Mar 2009 Discontinued - Phase-I for Inflammation in USA (PO)
  • 17 Mar 2009 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
  • 14 May 2008 Takeda acquires Millennium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top